Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;102(8):2001-2013.
doi: 10.1007/s00277-023-05286-3. Epub 2023 May 25.

Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma

Yuan-Hong Huang  1   2 , Chao-Ling Wan  1   2 , Hai-Ping Dai  3   4 , Sheng-Li Xue  5   6
Affiliations
Review

Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma

Yuan-Hong Huang et al. Ann Hematol. 2023 Aug.

Abstract

T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.

Keywords: Immunotherapy; T cell acute lymphoblastic leukemia/lymphoma; Targeted therapy.

PubMed Disclaimer

References

    1. Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541–1552. https://doi.org/10.1056/NEJMra1400972 - DOI - PubMed
    1. Litzow MR, Ferrando AA (2015) How i treat T-cell acute lymphoblastic leukemia in adults. Blood 126(7):833–841. https://doi.org/10.1182/blood-2014-10-551895 - DOI - PubMed
    1. Quist-Paulsen P, Toft N, Heyman M, Abrahamsson J, Griskevicius L, Hallbook H, Jonsson OG, Palk K, Vaitkeviciene G, Vettenranta K, Asberg A, Frandsen TL, Opdahl S, Marquart HV, Siitonen S, Osnes LT, Hultdin M, Overgaard UM, Wartiovaara-Kautto U, Schmiegelow K (2020) T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO all2008 protocol. Leukemia 34(2):347–357. https://doi.org/10.1038/s41375-019-0598-2 - DOI - PubMed
    1. Yin H, Hong M, Deng J, Yao L, Qian C, Teng Y, Li T, Wu Q (2022) Prognostic significance of comprehensive gene mutations and clinical characteristics in adult t-cell acute lymphoblastic leukemia based on next-generation sequencing. Front Oncol 12:811151. https://doi.org/10.3389/fonc.2022.811151 - DOI - PubMed - PMC
    1. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA et al (2017) The genomic landscape of pediatric and young adult t-lineage acute lymphoblastic leukemia. Nat Genet 49(8):1211–1218. https://doi.org/10.1038/ng.3909 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources